Reply

Affiliations

¹ Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² IIS-Fundacion Jimenez Diaz, School of Medicine, University Autonoma of Madrid, FRIAT and REDINREN, Madrid, Spain.
³ Department of Renal Medicine, University Hospitals Birmingham, Birmingham, UK.
⁴ Service de Nephrologie-HTA, dialyses, transplantation rénale, CHRU de Tours-Hospital Bretonneau, Tours, France.
⁵ Institute of Clinical Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
⁶ CNR-Institute of Clinical Physiology, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria.
⁷ Università Milano-Bicocca, Milan and Policlinico di Monza, Monza, Italy.
⁸ Division of Nephrology, Wuerzburg University Clinic, Würzburg, Germany.

Comment

Pantelis A Sarafidis et al. J Hypertens. 2022.

. 2022 Mar 1;40(3):624-626.

doi: 10.1097/HJH.0000000000003040.

¹ Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² IIS-Fundacion Jimenez Diaz, School of Medicine, University Autonoma of Madrid, FRIAT and REDINREN, Madrid, Spain.
³ Department of Renal Medicine, University Hospitals Birmingham, Birmingham, UK.
⁴ Service de Nephrologie-HTA, dialyses, transplantation rénale, CHRU de Tours-Hospital Bretonneau, Tours, France.
⁵ Institute of Clinical Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
⁶ CNR-Institute of Clinical Physiology, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria.
⁷ Università Milano-Bicocca, Milan and Policlinico di Monza, Monza, Italy.
⁸ Division of Nephrology, Wuerzburg University Clinic, Würzburg, Germany.

No abstract available

Comment on

Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
Sarafidis P, Ortiz A, Ferro CJ, Halimi JM, Kreutz R, Mallamaci F, Mancia G, Wanner C; ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardiovascular Medicine’ (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). Sarafidis P, et al. J Hypertens. 2021 Jun 1;39(6):1090-1097. doi: 10.1097/HJH.0000000000002776. J Hypertens. 2021. PMID: 33443971
Comment on 'Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease'.
Kawada T. Kawada T. J Hypertens. 2022 Mar 1;40(3):624. doi: 10.1097/HJH.0000000000003027. J Hypertens. 2022. PMID: 35103629 No abstract available.

1. Kawada T. Comment on ‘Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease’. J Hypertens 2022; 40:624.
1. Sarafidis P, Ortiz A, Ferro CJ, Halimi JM, Kreutz R, Mallamaci F, et al. Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens 2021; 39:1090–1097.
1. Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J 2021; 42:4891–4901.
1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446.
1. Kristensen SL, Docherty KF, Jhund PS, Bengtsson O, Demets DL, Inzucchi SE, et al. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. Eur Heart J 2020; 41:ehaa946.0939.